Ashwini Kumar Upadhyay Fake Medicine PIL: India SC Urged for Time-Bound Probe

• Advocate Ashwini Kumar Upadhyay has filed a Public Interest Litigation in the India Supreme Court seeking directions for time-bound investigation and trial in fake medicine cases.
• The PIL proposes investigations be completed within three months and trials within one year, citing the absence of standard procedures and Special Courts.
• It highlights gaps in the Drugs and Cosmetics Act 1940 enforcement and calls for stringent punishment and asset confiscation under the PMLA, Benami, and Black Money Acts.
• The petition also demands new Standard Operating Procedures for search and seizure, mandatory digital recording, and a sentencing policy for offenders.
• The petitioner asserts that fake medicines cause extensive public health damage, with associated deaths surpassing those from terrorism and other conflicts.

The petition contends that deaths due to fake medicines, vaccines, injections, and syrups surpass fatalities attributed to terrorism, naxalism, and riots, underscoring the critical need for judicial intervention.

A significant Public Interest Litigation (PIL) has been lodged before the India Supreme Court under Article 32, spearheaded by Advocate Ashwini Kumar Upadhyay. This Ashwini Kumar Upadhyay fake medicine PIL is pushing for comprehensive directives to both the central government and various states, aiming to establish a time-bound investigation and trial process for cases involving adulterated and spurious medicines, including injections, vaccines, and syrups. The petitioner specifically requests that investigations into fake medicine cases be concluded within three months, with trials finalized within one year.

The urgency of the petition stems from the alleged absence of a standardized investigation procedure, a lack of time-bound forensic examination protocols, and the non-existence of dedicated Special Courts fake medicine cases. Despite the Drugs and Cosmetics Act 1940 enforcement framework being in place, the petition asserts that the manufacturing and sale of counterfeit medicines continue to escalate, posing a severe threat to public health and safety across the nation. This legal challenge seeks to overhaul the current approach to combating this pervasive issue.

The PIL meticulously outlines several critical shortcomings within the existing legal and regulatory structure that, according to the petitioner, impede effective action against fake medicines. These include the absence of a Standard Operating Procedure (SOP) for conducting time-bound investigations and a defined timeline for the forensic examination of seized medicinal products. Crucially, the petition points to the lack of Special Courts dedicated to the swift trial of fake medicine cases, contributing to prolonged legal proceedings.

Furthermore, the petition argues that the current penalties under the Drugs and Cosmetics Act, 1940 are not sufficiently stringent to deter offenders. A significant concern raised is the failure to assess or confiscate properties acquired through the proceeds of crime under relevant legislation such as the Prevention of Money Laundering Act (PMLA), the Benami Property Act, and the Black Money Act. These identified lacunae, the petitioner contends, collectively result in the non-enforcement of existing laws, allowing the illicit trade of adulterated drugs to flourish unchecked.

Beyond establishing strict timelines for investigation and trial, the Ashwini Kumar Upadhyay fake medicine PIL seeks a range of additional reliefs designed to bolster enforcement. It calls for the time-bound assessment and confiscation of assets belonging to individuals involved in the fake medicine trade, including manufacturers, sellers, financiers, and their family members, utilizing provisions under the PMLA fake medicine confiscation, Benami Property Act, and Black Money Act. This move aims to dismantle the financial infrastructure supporting the illicit industry.

The petition also advocates for the formulation of clear SOPs governing the search, seizure, and sampling of adulterated and spurious medicines. It demands the prescription of a definite timeline for the submission of forensic science laboratory reports and mandates the digital recording and videography of all search, seizure, sampling, and inventory proceedings to ensure transparency and accountability. Additionally, the PIL requests the framing of a sentencing policy to ensure stringent punishment for those involved in the production and sale of fake medicines, a direction to the Law Commission to prepare a comprehensive report on the matter, and a declaration that sentences in fake medicine cases shall run consecutively, rather than concurrently.

The petitioner underscores the profound public health implications of adulterated drugs, asserting that fake medicines are responsible for a wide array of severe health issues, including Hepatitis B, liver problems, cardiovascular disease, and both respiratory and neurological damage. The PIL highlights that the harm inflicted upon the public is not merely physical but extends to mental health, the social fabric of society, and overall public order.

In a stark comparison, the petition claims that the number of deaths attributable to fake medicines, vaccines, injections, and syrups is higher than fatalities caused by terrorism, naxalism, and riots. This alarming assertion aims to emphasize the scale of the crisis and the urgent need for intervention. The petitioner firmly contends that this issue is not an isolated problem but a systemic challenge requiring the immediate and decisive attention of the Supreme Court of India, where a hearing on the matter is anticipated.

This Public Interest Litigation, if successful, could significantly alter the legal and regulatory landscape for pharmaceutical companies, distributors, and individuals involved in the production or sale of adulterated medicines in India. Lawyers and compliance officers should monitor this case for potential new Standard Operating Procedures, stricter enforcement timelines, and enhanced penalties, including asset confiscation, which would necessitate a review of existing compliance frameworks and risk assessments.

Source: Original reporting via Live Law